A REVIEW: TOCILIZUMAB, A RAY OF HOPE IN COVID-19 PNEUMONIA

Authors

  • DIVYA BM Department of Pharmacy Practice, PES College of Pharmacy, Bengaluru, Karnataka, India.

DOI:

https://doi.org/10.22159/ijms.2022.v10i3.42620

Keywords:

COVID-19, Cytokine release syndrome, Coronavirus disease 2019 pneumonia, Tocilizumab

Abstract

With the increased number of cases of coronavirus disease 2019 (COVID-19) all over the world which was discovered in December 2019 in Wuhan city of China, there are more positive rates and deaths encountered during the second wave due to this dreadful infection mainly focusing on youngsters diagnosed with COVID-pneumonia. Amidst this devastating situation, there is ray of hope by the emerging clinical trials on Tocilizumab, a potent interleukin-6 (Il-6) inhibitor which likely reduces the mortality of those patients having severe COVID-19 pneumonia as a result of Cytokine Release Syndrome. This syndrome is triggered by burst of inflammatory markers secondary to COVID-19 which is characterized by decrease in T-cells and Natural Killer cells, an increase in IL-6, fever, organ and tissue dysfunction, and an abnormal coagulation function eventually leading to death.

References

Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science 2020;368:473-4.

Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer 2018;6:56.

Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188-95.

Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood 2017;130:2295-306.

Liu D, Zhang T, Wang Y, Xia L. Tocilizumab: The key to stop coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Front Med 2020;7:571597.

Wadman M, Couzin-Frankel J, Kaiser J, Matacic C. A rampage through the body. Science 2020;368:356-60.

Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 2020;55:105954.

Picchianti Diamanti A, Rosado MM, Pioli C, Sesti G, Laganà B. Cytokine release syndrome in COVID-19 patients, a new scenario for an old concern: The fragile balance between infections and autoimmunity. Int J Mol Sci 2020;21:E3330.

Betancur JF, Navarro EP, Echeverry A, Moncada PA, Cañas CA, Tobón GJ. Hyperferritinemic syndrome: Still’s disease and catastrophic antiphospholipid syndrome triggered by fulminant Chikungunya infection: A case report of two patients. Clin Rheumatol 2015;34:1989-92.

Demirkol D, Yildizdas D, Bayrakci B, Karapinar B, Kendirli T, Koroglu TF, et al. Hyperferritinemia in the critically ill child with secondary hemophagocytic lymphohistiocytosis/sepsis/multiple organ dysfunction syndrome/macrophage activation syndrome: What is the treatment? Crit Care 2012;16:R52.

Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. Management of corona virus disease-19 (COVID-19): The Zhejiang experience. Zhejiang Da Xue Xue Bao Yi Xue Ban 2020;49:147-57.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130:2620-9.

Mastraianni A, Greco S, Apuzzo G, De Santis S, Oriolo C, Zanolini A. Subacutaneous tocilizumab treatment in patients with severe COVID-19 REalted cytokine release syndrome: An observational cohort study. Lancet 2020;24:100410.

Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 2018;23:943-7.

Samaee H, Mohsenzadegan M, Ala S, Maroufi SS, Moradimajd P. Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease. Int Immunopharmacol 2020;89:107018.

Zhao JY, Yan JY, Qu JM. Interpretations of “diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7)”. Chin Med J (Engl) 2020;133:1347-9.

Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single centre experience. J Med Virol 2020;92:814-8.

Klopfenstein T, Zayet S, Lohse JA, Balblanc C, Badie J, Royer PY, et al. Tocilizumab reduced intensive care unit admissions and/or mortality in COVID-19 patients. Méd Malad Infect 2020;50:397-400.

Gupta S, Wang W, Hayek SS, Chan L, Mathews KS, Melamed ML, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med 2021;181:41-51.

Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19-preliminary report. N Engl J Med 2021;384:1491-502.

RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet 2021;397:1637-45.

The First Affiliated Hospital of University of Science and Technology. The Efficacy and Safety of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia: A Multi-center, Randomized, Double-blinded Trial; 2020. Available from: ??? [Last accessed on 2021 May 15].

Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A 2020;117:10970-5.

Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol 2020;38:529-32.

Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmu Rev 2020;19:102568.

Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, et al. Tocilizumab in patients with severe COVID-19: Retrospective cohort study. Lancet Rheumatol 2020;2:474-84.

Stone JH, Frigault MJ, Serling-Boyd NJ, Fernandes AD, Harvey L, Foulkes AS, et al. Efficacy of tocilizumab in patients hospitalized with covid-19. N Engl J Med 2020;383:2333-44.

Salvarani C, Dolci G, Massari M, Merlo DF, Cavuto S, Savoldi L, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern Med 2021;181:24-31.

Rosas IO, Bräu N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med 2021;384:1503-16.

Published

21-04-2022

How to Cite

BM, D. (2022). A REVIEW: TOCILIZUMAB, A RAY OF HOPE IN COVID-19 PNEUMONIA. Innovare Journal of Medical Sciences, 10(3), 14–16. https://doi.org/10.22159/ijms.2022.v10i3.42620

Issue

Section

Review Article(s)